Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387642987> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W4387642987 abstract "PARP inhibitors have emerged as a promising class of anticancer agents approved for the treatment of ovarian, breast, prostate, and pancreatic cancer. These inhibitors target PARP enzymes involved in DNA repair pathways and exhibit remarkable efficacy in cancers with genetic deficiencies in the homologous recombination pathway responsible for mending DNA double-strand breaks. While all PARP inhibitors demonstrate potent and selective inhibition of PARP1 and PARP2, the key enzymes involved in DNA repair, each agent within the class possesses unique pharmacological profiles distinguishing them from one another. This review aims to comprehensively examine the properties of the entire PARP inhibitor class while emphasizing individual pharmacologic and pharmacokinetic distinctions that inform clinical recommendations. Currently, four agents, namely olaparib, rucaparib, niraparib, and talazoparib, have obtained approval in the United States and Europe. Olaparib, the first approved PARP inhibitor, has been extensively studied and is indicated for a wider range of cancer types. Niraparib and talazoparib, the more recent additions to the PARP inhibitor class, possess the longest half-lives and are formulated for convenient once-daily dosing, alleviating the pill burden for patients when compared to older agents. Moreover, talazoparib undergoes minimal hepatic metabolism, reducing the potential for drug-drug interactions. Notably, niraparib is the sole PARP inhibitor recommended for dose reduction in hepatically impaired populations, whereas talazoparib and olaparib should be dose reduced in renally impaired populations. The mechanisms underlying these dose adjustment recommendations are further explored in this review. Additionally, this review briefly covers veliparib, a PARP inhibitor under development, and two recently approved PARP inhibitors in China, fuzuloparib and pamiparib. Although significant progress has been made in understanding PARP inhibitors, there are several unanswered questions that remain, necessitating further research across a broader spectrum of cancer types within this evolving class of anticancer agents." @default.
- W4387642987 created "2023-10-15" @default.
- W4387642987 creator A5001321994 @default.
- W4387642987 creator A5016467089 @default.
- W4387642987 creator A5021815921 @default.
- W4387642987 creator A5047856599 @default.
- W4387642987 creator A5059295316 @default.
- W4387642987 date "2023-10-01" @default.
- W4387642987 modified "2023-10-15" @default.
- W4387642987 title "PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics" @default.
- W4387642987 cites W2082618949 @default.
- W4387642987 cites W2112241575 @default.
- W4387642987 cites W2147154862 @default.
- W4387642987 cites W2205459102 @default.
- W4387642987 cites W2209898522 @default.
- W4387642987 cites W2367214440 @default.
- W4387642987 cites W2528228811 @default.
- W4387642987 cites W2531509304 @default.
- W4387642987 cites W2592941899 @default.
- W4387642987 cites W2593067736 @default.
- W4387642987 cites W2595030994 @default.
- W4387642987 cites W2597062310 @default.
- W4387642987 cites W2732346161 @default.
- W4387642987 cites W2900056609 @default.
- W4387642987 cites W2921491449 @default.
- W4387642987 cites W2936141205 @default.
- W4387642987 cites W2954614519 @default.
- W4387642987 cites W2991232411 @default.
- W4387642987 cites W3010402335 @default.
- W4387642987 cites W3013909635 @default.
- W4387642987 cites W3133740787 @default.
- W4387642987 cites W3137618571 @default.
- W4387642987 cites W3150665659 @default.
- W4387642987 cites W3153187965 @default.
- W4387642987 cites W3153250761 @default.
- W4387642987 cites W3158906188 @default.
- W4387642987 cites W3171888425 @default.
- W4387642987 cites W3184289098 @default.
- W4387642987 cites W3192151430 @default.
- W4387642987 cites W4205422786 @default.
- W4387642987 cites W4214939689 @default.
- W4387642987 doi "https://doi.org/10.1053/j.seminoncol.2023.09.005" @default.
- W4387642987 hasPublicationYear "2023" @default.
- W4387642987 type Work @default.
- W4387642987 citedByCount "0" @default.
- W4387642987 crossrefType "journal-article" @default.
- W4387642987 hasAuthorship W4387642987A5001321994 @default.
- W4387642987 hasAuthorship W4387642987A5016467089 @default.
- W4387642987 hasAuthorship W4387642987A5021815921 @default.
- W4387642987 hasAuthorship W4387642987A5047856599 @default.
- W4387642987 hasAuthorship W4387642987A5059295316 @default.
- W4387642987 hasConcept C182979987 @default.
- W4387642987 hasConcept C2778480876 @default.
- W4387642987 hasConcept C2779138821 @default.
- W4387642987 hasConcept C2779962180 @default.
- W4387642987 hasConcept C2781312401 @default.
- W4387642987 hasConcept C502942594 @default.
- W4387642987 hasConcept C54355233 @default.
- W4387642987 hasConcept C552990157 @default.
- W4387642987 hasConcept C71924100 @default.
- W4387642987 hasConcept C82381507 @default.
- W4387642987 hasConcept C86803240 @default.
- W4387642987 hasConcept C98274493 @default.
- W4387642987 hasConceptScore W4387642987C182979987 @default.
- W4387642987 hasConceptScore W4387642987C2778480876 @default.
- W4387642987 hasConceptScore W4387642987C2779138821 @default.
- W4387642987 hasConceptScore W4387642987C2779962180 @default.
- W4387642987 hasConceptScore W4387642987C2781312401 @default.
- W4387642987 hasConceptScore W4387642987C502942594 @default.
- W4387642987 hasConceptScore W4387642987C54355233 @default.
- W4387642987 hasConceptScore W4387642987C552990157 @default.
- W4387642987 hasConceptScore W4387642987C71924100 @default.
- W4387642987 hasConceptScore W4387642987C82381507 @default.
- W4387642987 hasConceptScore W4387642987C86803240 @default.
- W4387642987 hasConceptScore W4387642987C98274493 @default.
- W4387642987 hasLocation W43876429871 @default.
- W4387642987 hasOpenAccess W4387642987 @default.
- W4387642987 hasPrimaryLocation W43876429871 @default.
- W4387642987 hasRelatedWork W2003243316 @default.
- W4387642987 hasRelatedWork W2016425953 @default.
- W4387642987 hasRelatedWork W2604684522 @default.
- W4387642987 hasRelatedWork W2807317098 @default.
- W4387642987 hasRelatedWork W2901011044 @default.
- W4387642987 hasRelatedWork W2914979195 @default.
- W4387642987 hasRelatedWork W3009707110 @default.
- W4387642987 hasRelatedWork W3134914296 @default.
- W4387642987 hasRelatedWork W3135348276 @default.
- W4387642987 hasRelatedWork W4296617455 @default.
- W4387642987 isParatext "false" @default.
- W4387642987 isRetracted "false" @default.
- W4387642987 workType "article" @default.